Lumentum drops -13.94% amid Marvell merger and wider selloff
Lumentum drops -13.94% amid Marvell merger and wider selloff
Conclusion: Lumentum's 13.94% drop on Nov 20, 2026 mostly reflects the Marvell merger and the wider AI-hardware selloff, not a weakening in optical demand. The company's own filings describe demand outrunning supply, which supports pricing and margins. But "capacity sold out through 2029" is a broker's characterization, not a company statement, and the stock now trades on Marvell's share price as much as on Lumentum's operations.
Data as of: Regular-session close on Friday, Nov 20, 2026 (16:15 ET). Prepared Nov 21, 2026 (Asia/Shanghai).
1. The move and what drove it
- LITE closed at , down from . Market cap was .
- The deal is an all-stock merger with Marvell, announced Nov 2, with an implied enterprise value of $115B and closing expected in the first half of 2028. Lumentum holders receive a fixed 4.5 Marvell shares per share (CNBC; Yahoo/Investing.com).
- MRVL closed at , on the day. At that price, 4.5 MRVL shares are worth , so LITE traded at a to the implied deal value. (Calculation: 4.5 × 122.28 = 550.26; 460.54 ÷ 550.26 − 1.)
- CNBC reports the market has also soured on the AI trade broadly, citing borrowing costs and political pushback on data-center construction. On Nov 20 the Nasdaq fell and optical peers (Coherent, AAOI, AXT) sold off with LITE (Investing.com). A Form 144 filing for a potential insider sale was also reported that day.
So the premise that the drop reflects AI shifting toward optical interconnects is not what the price action shows. Optical is the long-term driver in management's narrative, but the near-term move is about deal mechanics and sentiment.
2. Demand and supply evidence
- The company's Form 10-Q for the quarter ended Sep 26, 2026 says demand "is outpacing our current supply, which has required us to make decisions on supply allocation," and that it is investing in internal and contract manufacturing capacity (10-Q). This supports a supply-constrained market.
- The "sold out through 2029" language comes from B. Riley's Nov 2 note, which named LITE its top AI optics pick (Investing.com). I did not find the company stating it. Treat it as an analyst view.
- Company-reported commitments: a second major NPO/CPO win backed by purchase commitments above $5B, and a September capacity reservation agreement with a customer. That customer paid a first installment of $100.0M (IR release; 10-Q).
- Pump-laser and OCS demand is the main growth driver. The Yahoo/Investing.com piece cites take-or-pay agreements with hyperscalers, but that is article context, not a company disclosure.
3. Revenue growth
- Q1 FY27 (ended Sep 26) revenue was , up more than 136% year over year (Investing.com).
- Q2 guidance is $1.575B–$1.625B. The midpoint of implies about sequential growth. Management says this is about $350M of sequential growth.
- OCS (optical circuit switching) is described as becoming a multi-billion-dollar annual revenue stream. That is management's expectation, not a guided number.
4. Margins
- Q1 GAAP gross margin was 51.0% and non-GAAP gross margin 53.2%. Non-GAAP operating margin was 42.3% (IR release).
- Q2 guidance calls for non-GAAP operating margin of 45.0%–46.0% and non-GAAP EPS of $5.90–$6.20.
- The tightness helps pricing, but the 10-Q's forward-looking risks flag average selling price declines and mix as margin headwinds. Cloud modules are improving on gross margin.
5. Execution and balance-sheet risks
- Capex and cash conversion: Q1 capex was $229.8M, about of revenue. Operating cash flow was $267.7M, leaving of free cash flow after capex. Inventory rose $114.2M and prepayments rose $114.2M (10-Q).
- Supplier concentration: One contract manufacturer accounted for 14% of net inventory purchases in the quarter.
- Dilution and convertibles: The Q4 FY26 GAAP net loss of $7.2B came mainly from a one-time, non-cash $7.8B charge on converting debt to equity. The 2032 notes raised about $1.25B net (IR release; Yahoo/Investing.com).
- Deal risk: Closing is expected in H1 2028, subject to shareholder and regulatory approvals that could include China. Investor-rights firms have opened inquiries into whether the exchange ratio is fair. Marvell reports on Dec 1 and an S-4 is due. These are the near-term catalysts for LITE's price.
- Customer concentration: The 10-Q and press coverage point to hyperscaler concentration.
Analysis
- The demand signal is real and company-reported: supply is short, and customers are prepaying and committing. That supports Q2 revenue and margin guidance.
- The equity is not a clean read on that demand. Until the Marvell deal closes or breaks, LITE's price is tied to MRVL, currently at a 16.3% discount to implied value. The ratio fixes Lumentum's share of the combined company, so the stock's downside and upside are shared with Marvell.
- The execution risks are capacity build-out, cash conversion, supplier and customer concentration, and deal approval. Each could matter more to the share price than the optical demand story in the next few quarters.
- What would change this view: a clear company statement on capacity sold-out status, a Marvell update showing the ratio is revisited or the deal is re-priced, or Q2 results that confirm the guided margin expansion.
Sources
- Quotes: Driven marketQuotes, LITE and MRVL, Nov 20, 2026 regular-session close (16:15 ET).
- Lumentum Q1 FY2027 results release, Nov 2, 2026 (primary)
- Lumentum Form 10-Q, quarter ended Sep 26, 2026 (primary)
- CNBC, Nov 19, 2026: Lumentum CEO defends Marvell deal
- Investing.com, Nov 20, 2026: Why is Lumentum stock sliding today?
- Yahoo/Investing.com, Nov 19, 2026: Lumentum's sales surged 137%—so why is its stock crashing?
- Investing.com, Nov 2, 2026: B. Riley names LITE top AI optics pick (analyst view; "sold out through 2029" is B. Riley's claim)